The historical rank and industry rank for Gufic Biosciences's OCF Margin % or its related term are showing as below:
BOM:509079'
s OCF Margin % Range Over the Past 10 Years
Min: -3.91 Med: 3.14 Max: 17.89
Current: 4.76
During the past 13 years, the highest OCF Margin % of Gufic Biosciences was 17.89%. The lowest was -3.91%. And the median was 3.14%.
BOM:509079's OCF Margin % is ranked worse than 61.55% of 957
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs BOM:509079: 4.76
Gufic Biosciences OCF Margin % Related Terms
Gufic Biosciences OCF Margin % Historical Data
* Premium members only.
The historical data trend for Gufic Biosciences's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gufic Biosciences OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Gufic Biosciences's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gufic Biosciences (BOM:509079) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gufic Biosciences and its competitors. According to the industry distribution chart, Gufic Biosciences ranks #589 out of 957 companies in the Drug Manufacturers industry, placing it in the top 61.5%.
Is Gufic Biosciences' OCF Margin % too high?
Gufic Biosciences' current OCF Margin % is 0.00%. Based on the distribution chart, Gufic Biosciences ranks #589 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Gufic Biosciences has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gufic Biosciences ranks #589 out of 957 companies for OCF Margin %. This places Gufic Biosciences in the lower half of its industry. The industry median OCF Margin % is 9.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gufic Biosciences and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gufic Biosciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹407.00, compared to a current price of ₹385.75 — trading 5.2% below its estimated fair value. The current OCF Margin % is 0.00%. Gufic Biosciences' overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gufic Biosciences (BOM:509079) Overvalued in 2026?
Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued.
The current stock price of ₹385.75 is trading 5.2% below its estimated GF Value™ of ₹407.00.
GuruFocus considers Gufic Biosciences to be Fairly Valued.
Key valuation signals for BOM:509079:
OCF Margin %: 0.00%
GF Value™: ₹407.00 vs. price of ₹385.75 (5.2% below fair value)
No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
76GF Score
Get the complete analysis for BOM:509079
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:509079 has been successfully added to your 
